Investigatio quadrigae apud Institutum Cancri Investigationis (CSI) Universitatis Nationalis Singaporis novum peptide medicamento vocato FFW evolvit, quod evolutionem carcinomatis (HCC) vel primariae hepatocellulares impedire potest. iecoris cancer . Haec inventio limes ianuam aperit ad cancrum hepatis efficacius curationi et effectus latus deminutus.
SALL4 is a protein associated with tumor growth and has been used as a prognostic marker and drug target for HCC, lung cancer and leukemia. It is usually present in a growing fetus, but is inactive in adult tissues. In some cancers, such as HCC, SALL4 is reactivated, leading to tuberculum incrementum.
In proteins medicamento moleculis hoc actum, ut SALL4, NuRD, plerumque eget dapibus ut in scopum parva "sinum" in III-D structuram, ubi medicamento potest, est moleculas, et munus. In primo investigationes, ea inventa est in alio Interacts SALL3 dapibus dapibus NuRD formatam, quae in societate est crucial ad progressionem cancer ut ex Hec. SALL4 disposito hac investigationis quadrigis non expecto, loculos, et disposito biomolecules angustos se de commercio SALL4 et NuRD. Studies deprehendi non possit facere ut obturarent capita commercio illo redigendum tumor et tumor cellula motus cell mortem.
FFW can effectively block protein-protein interactions, and does not require “pockets” to take effect. The research team also found that when combined with sorafenib, FFW can reduce the growth of sorafenib-resistant HCC. Although most targeted therapies are small-molecule drugs, well-designed peptide drugs (such as FFW) tend to have higher selectivity than large-molecule surfaces and are less toxic than small molecules.
Singapore indagator Dr Liu See Hui dixit: Ex indicium habemus fide in structuram et global gene expressio, et hoc continue studere in peptides et alia Mammalia ut eventually similiumque idoneum faciet illos gradus orci mauris et bonum aegris.
